NCT05702762

Brief Summary

The purpose of this research study is to determine if gentamicin is as effective treatment of acute uncomplicated cystitis (urinary tract infection) using aminoglycosides versus the current standards of care. The current standards of care in our region are often to prescribe a multi-day antibiotic prescription that is taken multiple times per day whereas gentamicin will be a one-time dose in the emergency department. Gentamicin is the medicine being studied.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
160

participants targeted

Target at P75+ for phase_2

Timeline
Completed

Started Oct 2022

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 22, 2022

Completed
9 days until next milestone

Study Start

First participant enrolled

October 1, 2022

Completed
4 months until next milestone

First Posted

Study publicly available on registry

January 27, 2023

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 30, 2023

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

June 30, 2024

Completed
Last Updated

January 27, 2023

Status Verified

January 1, 2023

Enrollment Period

9 months

First QC Date

September 22, 2022

Last Update Submit

January 18, 2023

Conditions

Keywords

gentamicinsingle dose antibiotic treatment

Outcome Measures

Primary Outcomes (2)

  • Clinical Resolution

    If patient is or is not still having any pain with urination, urinary frequency or urinary urgency

    7 days from presentation

  • Clinical Resolution

    If patient is or is not still having any pain with urination, urinary frequency or urinary urgency

    30 days from presentation

Study Arms (2)

Gentamicin

ACTIVE COMPARATOR

Subjects will be given one (1) injection intramuscular gentamicin 5 mg/kg (actual body weight unless patient is \>120% ideal body weight in which case adjusted body weight will be utilized).

Drug: Gentamicin

Standard of Care

ACTIVE COMPARATOR

Oral antibiotic prescription

Drug: Standard of Care

Interventions

5 mg/kg intramuscular injection

Gentamicin

Usual oral antibiotic multi-day dosing based on local antibiogram

Also known as: Oral dose regimen for simple urinary tract infection: Including cephalexin, cefdinir, sulfamethoxazole/trimethoprim, and nitrofurantoin at appropriate dose, frequency, and duration
Standard of Care

Eligibility Criteria

Age18 Years+
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • At least 18 years of age, woman, pre-menopausal, non-pregnant with clinical signs of urinary tract infection and nitrite positive urine.

You may not qualify if:

  • Contraindications include hypersensitivity to gentamicin or other aminoglycosides.
  • Patients younger than 18 years of age.
  • Pregnant or post-menopausal patients.
  • Patients without symptoms of UTI, nitrite negative urine, or any patient with working diagnosis of complicated UTI such as pyelonephritis or any patient catheterized.
  • ANY history of pre-existing renal impairment.
  • Patient that has any listed or reports taking ANY nephrotoxic or wit drug-drug interaction medication in the past 7 days (see Appendix 5).
  • ANY history of hearing loss, tinnitus, or vertigo.
  • ANY patient that has received general anesthesia or neuromuscular blockade in past 7 days.
  • Patients with ANY history of neuromuscular disorders including: myasthenia gravis, amyotrophic lateral sclerosis, muscular dystrophy, botulism, congenital myasthenic syndromes, congenital myopathies, myositis, Lambert-Eaton syndrome, mitochondrial myopathy, myotonic dystrophy, neuromyotonia, or peripheral neuropathy.
  • Patients with ANY history of thrombocytopenia.
  • Patient that has any listed or reports taking ANY anticoagulants in the past 7 days.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

St. Elizabeth Youngstown Hospital

Youngstown, Ohio, 44501, United States

RECRUITING

Related Publications (6)

  • Goodlet KJ, Benhalima FZ, Nailor MD. A Systematic Review of Single-Dose Aminoglycoside Therapy for Urinary Tract Infection: Is It Time To Resurrect an Old Strategy? Antimicrob Agents Chemother. 2018 Dec 21;63(1):e02165-18. doi: 10.1128/AAC.02165-18. Print 2019 Jan.

    PMID: 30397061BACKGROUND
  • Durkin MJ, Keller M, Butler AM, Kwon JH, Dubberke ER, Miller AC, Polgreen PM, Olsen MA. An Assessment of Inappropriate Antibiotic Use and Guideline Adherence for Uncomplicated Urinary Tract Infections. Open Forum Infect Dis. 2018 Aug 10;5(9):ofy198. doi: 10.1093/ofid/ofy198. eCollection 2018 Sep.

    PMID: 30191156BACKGROUND
  • Ababneh M, Harpe S, Oinonen M, Polk RE. Trends in aminoglycoside use and gentamicin-resistant gram-negative clinical isolates in US academic medical centers: implications for antimicrobial stewardship. Infect Control Hosp Epidemiol. 2012 Jun;33(6):594-601. doi: 10.1086/665724. Epub 2012 Apr 19.

    PMID: 22561715BACKGROUND
  • Foxman B. The epidemiology of urinary tract infection. Nat Rev Urol. 2010 Dec;7(12):653-60. doi: 10.1038/nrurol.2010.190.

    PMID: 21139641BACKGROUND
  • Kang CI, Kim J, Park DW, Kim BN, Ha US, Lee SJ, Yeo JK, Min SK, Lee H, Wie SH. Clinical Practice Guidelines for the Antibiotic Treatment of Community-Acquired Urinary Tract Infections. Infect Chemother. 2018 Mar;50(1):67-100. doi: 10.3947/ic.2018.50.1.67.

    PMID: 29637759BACKGROUND
  • Sanchez GV, Babiker A, Master RN, Luu T, Mathur A, Bordon J. Antibiotic Resistance among Urinary Isolates from Female Outpatients in the United States in 2003 and 2012. Antimicrob Agents Chemother. 2016 Apr 22;60(5):2680-3. doi: 10.1128/AAC.02897-15. Print 2016 May.

    PMID: 26883714BACKGROUND

Related Links

MeSH Terms

Conditions

Urinary Tract Infections

Interventions

GentamicinsStandard of CareCefdinirSulfamethoxazoleTrimethoprimTime

Condition Hierarchy (Ancestors)

InfectionsUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital Diseases

Intervention Hierarchy (Ancestors)

AminoglycosidesGlycosidesCarbohydratesQuality Indicators, Health CareQuality of Health CareHealth Services AdministrationHealth Care Quality, Access, and EvaluationCephalosporinsbeta-LactamsLactamsAmidesOrganic ChemicalsThiazinesSulfur CompoundsHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-RingHeterocyclic CompoundsBenzenesulfonamidesSulfonamidesSulfanilamidesAniline CompoundsAminesBenzene DerivativesHydrocarbons, AromaticHydrocarbons, CyclicHydrocarbonsSulfonesPyrimidinesHeterocyclic Compounds, 1-RingPhysical Phenomena

Central Study Contacts

Jacob Sieger, DO

CONTACT

Vincent Peyko, PharmD

CONTACT

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: Multicenter prospective open label randomized controlled study
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 22, 2022

First Posted

January 27, 2023

Study Start

October 1, 2022

Primary Completion

June 30, 2023

Study Completion

June 30, 2024

Last Updated

January 27, 2023

Record last verified: 2023-01

Data Sharing

IPD Sharing
Will not share

Locations